Remove 2021 Remove Clinical Pharmacology Remove Therapies
article thumbnail

Vamorolone

New Drug Approvals

Corticosteroid therapy is the current standard of care for DMD despite relatively high rates of adverse effects. 7 (2021) 13. [70] 75,76 This also results in decreased glucocorticoid receptor-drive transactivation, ultimately improving the safety profile of vamorolone as compared to other corticosteroid therapies. Goemans, S.

FDA 62
article thumbnail

Landiolol

New Drug Approvals

“Pharmacokinetics of landiolol hydrochloride, a new ultra-short-acting beta-blocker, in patients with cardiac arrhythmias” Clinical Pharmacology and Therapeutics. 28 October 2021. New Drug Therapy Approvals 2024 (PDF). February 2021). . ^ Atarashi H, Kuruma A, Yashima M, Saitoh H, Ino T, Endoh Y, et al.

FDA 62
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Antibody Drug Conjugates: windows of opportunity

Drug Target Review

These therapies have broadened treatment options for patients to expand beyond the more traditional small molecule drug alternatives. Patients and caregivers also assess the benefits offered by different therapies, weighing the progression-free survival with their off-target effects.

article thumbnail

Eplontersen

New Drug Approvals

. “Characteristics of Patients with Hereditary Transthyretin Amyloidosis-Polyneuropathy (ATTRv-PN) in NEURO-TTRansform, an Open-label Phase 3 Study of Eplontersen” Neurology and Therapy. World Health Organization (2021). 12 (1): 267–287. doi : 10.1007/s40120-022-00414-z. PMC 9837340. PMID 36525140. 88 (12): 5389–5398.

article thumbnail

Bristol Myers Squibb Data at the EADV 30th Anniversary Congress Highlight the Growing Body of Evidence on Deucravacitinib and Scientific Advancements for Patients with Serious Dermatologic Diseases

The Pharma Data

Deucravacitinib demonstrated efficacy no matter baseline characteristics, including weight , disease severity and former treatment with biologic or non-biologic therapies. People with psoriasis report an impression on their emotional well-being, straining both personal and professional relationships and causing a reduced quality of life.

Disease 52
article thumbnail

Metabolism of macrocyclic drugs

Metabolite Tales Blog

A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Figure 2 Human metabolism of glecaprevir Involvement of gut bacteria Grazoprevir (MK5172) is also used as part of combination therapy to treat chronic hepatitis C. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION.

Drugs 52
article thumbnail

Metabolism of de novo designed macrocyclic drugs

Metabolite Tales Blog

A combination therapy of glecaprevir and pibrentasvir has recently been implicated in a case of liver injury. Figure 2 Human metabolism of glecaprevir Involvement of gut bacteria Grazoprevir (MK5172) is also used as part of combination therapy to treat chronic hepatitis C. link] [9] PHARMACOLOGY/TOXICOLOGY NDA REVIEW AND EVALUATION.

Drugs 52